Press Releases

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

December 8, 2015

AgeneBio Appoints Richard Mohs, PhD, Vice President of Clinical Development

Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug…

November 24, 2015

AgeneBio to Present at Future of Innovation in Medicine Conference

Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical…

October 22, 2015

AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer’s Disease

Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the…

October 6, 2015

AgeneBio to Present at BIO Investor Forum 2015

BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at…

January 7, 2015

AgeneBio CEO Jerry McLaughlin to Present at Biotech Showcase 2015

BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the…